Larimar Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Larimar Therapeutics has a total shareholder equity of $81.7M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $95.9M and $14.2M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$86.79m |
| Equity | US$81.72m |
| Total liabilities | US$14.22m |
| Total assets | US$95.94m |
Recent financial health updates
We're Hopeful That Larimar Therapeutics (NASDAQ:LRMR) Will Use Its Cash Wisely
Nov 13
Here's Why We're Not Too Worried About Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Situation
May 19Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth
Feb 02Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Deliver On Growth Plans?
Sep 02We Think Larimar Therapeutics (NASDAQ:LRMR) Needs To Drive Business Growth Carefully
Mar 21Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Invest In Growth?
Dec 18Recent updates
We're Hopeful That Larimar Therapeutics (NASDAQ:LRMR) Will Use Its Cash Wisely
Nov 13Here's Why We're Not Too Worried About Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Situation
May 19Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth
Feb 02Laramar Therapeutics issued patent for lead pipeline candidate
Oct 20Larimar Therapeutics prices ~$70M stock offering
Sep 14Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Deliver On Growth Plans?
Sep 02Larimar Therapeutics GAAP EPS of -$0.47
Aug 11We Think Larimar Therapeutics (NASDAQ:LRMR) Needs To Drive Business Growth Carefully
Mar 21Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Invest In Growth?
Dec 18Larimar under pressure as FDA puts clinical hold on CTI-1601 program
May 26Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth
Feb 08
Larimar, Avadel, Applied Therapeutics will added to Nasdaq Biotechnology Index
Dec 15Larimar completes dosing in Friedreich’s Ataxia, provides program update
Dec 08Larimar Therapeutics (LRMR) Investor Presentation - Slideshow
Nov 16Larimar Therapeutics reports Q3 results
Nov 10Financial Position Analysis
Short Term Liabilities: LRMR's short term assets ($90.2M) exceed its short term liabilities ($9.5M).
Long Term Liabilities: LRMR's short term assets ($90.2M) exceed its long term liabilities ($4.7M).
Debt to Equity History and Analysis
Debt Level: LRMR is debt free.
Reducing Debt: LRMR has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: LRMR has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: LRMR has sufficient cash runway for 2.2 years if free cash flow continues to reduce at historical rates of 3.8% each year.